CLYMClimb Bio Inc
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+17% of shares).
Rangebound, no clear trend. Price is −1% vs its 200-day average.
A crowded short, settled Sep 30, 2026, about a week of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CLYM is trading
Climb Bio Inc is +394% over the past year while the S&P 500 is +16%: 378 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −0.69%
vs 200-day average · below trend, but not far
- RSI (14)
- 41
RSI (14) · neutral
- Below its 52-week high
- 43%
Below its 52-week high
Details›
- Last close2026-10-23
- $10.18
- 1 monthS&P 500 −0.94%
- −14%
- 1 yearS&P 500 +16%
- +394%
- 5 yearsS&P 500 +86%
- −37%
- vs 50-day average$13.33
- −24%
- 52-week high
- $17.83
- 52-week low
- $1.64
- Annualised volatility
- 90%
| Year | Return |
|---|---|
| 2026 (year to date) | +154% |
| 2025 | +122% |
| 2024 | −33% |
| 2023 | −26% |
| 2022 | −65% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 2 of 5 | −1.2% |
| Feb | 5 | 3 of 5 | +8.9% |
| Mar | 5 | 1 of 5 | −9.0% |
| Apr | 5 | 4 of 5 | +29% |
| May | 5 | 3 of 5 | +6.9% |
| Jun | 5 | 2 of 5 | −1.8% |
| Jul | 5 | 3 of 5 | +4.3% |
| Aug | 5 | 2 of 5 | +11% |
| Sep | 6 | 1 of 6 | −13% |
| Oct | 6 | 2 of 6 | −6.0% |
| Nov | 5 | 0 of 5 | −13% |
| Dec | 5 | 3 of 5 | +18% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.